ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$11.69 USD
-0.57 (-4.61%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $11.69 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
ADMA 11.69 -0.57(-4.61%)
Will ADMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADMA
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
Navigate Market Turbulence With These 4 Low-Beta Stocks
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Other News for ADMA
Undercovered Dozen: Burberry, Vinci SA, Lyft, PureCycle +
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
ADMA Biologics Appoints Brad Tade as New CFO and Treasurer
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'